Antengene Corporation Limited (06996.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−14.9x

Market Cap

HKD 2.23B

MomentumView details →

1D Return

−0.70%

YTD Return

−6.20%

RSI (14)

37.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−14.9x

Market Cap

HKD 2.23B

RSI (14)

37.6

MomentumView details →

1D Return

−0.70%

YTD Return

−6.20%

ProfitabilityView details →

Gross Margin

89.60%

Net Margin

−27.70%

EBITDA Margin

−14.65%

ROE (TTM)

−19.51%

ROA (TTM)

−11.72%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+174.27%

EPS YoY

+85.71%

FCF YoY

+86.84%

Revenue CAGR 3Y

−13.03%

EPS CAGR 3Y

+25.49%

EBITDA YoY

+93.37%

EarningsView details →

EPS (Actual)

HKD 0.39

EPS Surprise

−8.10%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−8.10%

Rev Surprise

14.68%

Capital & dividendView details →

Debt/Equity

0.28x

Current Ratio

4.95x

Quick Ratio

4.91x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

642.50M

Net Income (TTM)

−177.99M

Op. CF (TTM)

—

Next earningsMar 19, 2027 →

Latest newsMore news →

Antengene announced that its Phase I ATTRACT study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B-cell related autoimmune diseases, received approval from the Australian Human Research Ethics Committee and completed the Clinical Trial Notification submission to the Therapeutic Goods Administration.11d ago

Antengene Corporation reported interim results for the six months ended June 30, 2026, with revenue of RMB 513 million, up 865% year-over-year, and a net profit of RMB 216 million, reversing a loss of RMB 76.378 million in the prior-year period.14d ago

Similar companies

Day One Biopharmaceuticals, Inc.DAWN Kodiak Sciences Inc.KOD PegBio Co., Ltd.02565.HK Mesoblast LimitedMESO Rapport Therapeutics, Inc. Common StockRAPP Revolution Medicines, Inc. WarrantRVMDW Find similar companies →

Latest newsMore news →

Antengene announced that its Phase I ATTRACT study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B-cell related autoimmune diseases, received approval from the Australian Human Research Ethics Committee and completed the Clinical Trial Notification submission to the Therapeutic Goods Administration.11d ago Antengene Corporation reported interim results for the six months ended June 30, 2026, with revenue of RMB 513 million, up 865% year-over-year, and a net profit of RMB 216 million, reversing a loss of RMB 76.378 million in the prior-year period.14d ago